| Year |
Title |
Altmetric |
| 2023
|
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA.
108:705-716.
2023
|
|
| 2023
|
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
Blood Advances.
7:196-204.
2023
|
|
| 2023
|
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
2023
|
|
| 2023
|
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG
2023
|
|
| 2023
|
Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.
The hematology journal : the official journal of the European Haematology Association / EHA.
108:42-47.
2023
|
|
| 2022
|
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML).
Clinical Lymphoma, Myeloma and Leukemia.
22:S208-S209.
2022
|
|
| 2022
|
AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT).
Clinical Lymphoma, Myeloma and Leukemia.
22:S229-S230.
2022
|
|
| 2022
|
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions.
Clinical Lymphoma, Myeloma and Leukemia.
22:S231-S232.
2022
|
|
| 2022
|
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
Blood Advances.
6:4085-4092.
2022
|
|
| 2022
|
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood.
140:112-120.
2022
|
|
| 2022
|
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Journal of Clinical Oncology.
40:1574-1582.
2022
|
|
| 2021
|
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood.
138:2810-2827.
2021
|
|
| 2021
|
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Journal of Clinical Oncology.
39:3737-3746.
2021
|
|
| 2021
|
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
Leukemia.
35:3278-3281.
2021
|
|
| 2021
|
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Leukemia.
35:2854-2861.
2021
|
|
| 2021
|
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
International Journal of Laboratory Hematology.
43:426-432.
2021
|
|
| 2021
|
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.
Blood Cancer Journal.
11.
2021
|
|
| 2021
|
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood.
137:751-762.
2021
|
|
| 2021
|
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
Blood Advances.
5:504-512.
2021
|
|
| 2021
|
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia
2021
|
|
| 2021
|
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203
2021
|
|
| 2020
|
Diagnosis and Treatment of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC).
American Journal of Clinical Pathology.
154:731-741.
2020
|
|
| 2020
|
Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
Hematology/Oncology and Stem Cell Therapy.
13:143-146.
2020
|
|
| 2020
|
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: A SWOG report.
Biomarker Research.
8.
2020
|
|
| 2020
|
American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.
Blood Advances.
4:3528-3549.
2020
|
|
| 2020
|
Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.
Value in Health.
23:1034-1039.
2020
|
|
| 2020
|
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Lancet Haematology.
7:e601-e612.
2020
|
|
| 2020
|
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
American Journal of Hematology.
95:662-671.
2020
|
|
| 2020
|
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia.
Jco Oncology Practice.
16:E464-E475.
2020
|
|
| 2020
|
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).
Blood Advances.
4:1683-1689.
2020
|
|
| 2020
|
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood.
135:463-471.
2020
|
|
| 2020
|
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities—AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Clinical Lymphoma, Myeloma and Leukemia.
20:24-30.
2020
|
|
| 2019
|
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.
Blood.
134:33.
2019
|
|
| 2019
|
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Leukemia.
33:2599-2609.
2019
|
|
| 2019
|
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML.
New England Journal of Medicine.
381:1728-1740.
2019
|
|
| 2019
|
Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia.
New England Journal of Medicine.
381:432-443.
2019
|
|
| 2019
|
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403.
Blood.
133:1548-1559.
2019
|
|
| 2019
|
Shifting paradigms in the treatment of older adults with AML.
Seminars in Hematology.
56:110-117.
2019
|
|
| 2019
|
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).
Leukemia Research.
78:29-33.
2019
|
|
| 2019
|
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Leukemia.
33:371-378.
2019
|
|
| 2019
|
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
Leukemia.
33:554-558.
2019
|
|
| 2019
|
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
Blood Advances.
3:1939-1949.
2019
|
|
| 2018
|
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL.
New England Journal of Medicine.
379:2517-2528.
2018
|
|
| 2018
|
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*
2018
|
|
| 2018
|
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Leukemia Research.
74:64-67.
2018
|
|
| 2018
|
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
Leukemia.
32:2352-2362.
2018
|
|
| 2018
|
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood.
132:1125-1133.
2018
|
|
| 2018
|
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Blood.
131:2782-2788.
2018
|
|
| 2018
|
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.
New England Journal of Medicine.
378:2386-2398.
2018
|
|
| 2018
|
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Leukemia Research.
67:17-20.
2018
|
|
| 2018
|
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood.
131:1415-1424.
2018
|
|
| 2018
|
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.
Biopreservation and Biobanking.
16:42-52.
2018
|
|
| 2018
|
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.
American Journal of Hematology.
93:E49-E52.
2018
|
|
| 2018
|
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Blood.
131:387-396.
2018
|
|
| 2017
|
Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study swog s1117.
Journal of Clinical Oncology.
35:2745-2753.
2017
|
|
| 2017
|
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
2017
|
|
| 2017
|
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
Cancer.
123:2472-2481.
2017
|
|
| 2017
|
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
Blood.
129:1763-1767.
2017
|
|
| 2017
|
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Blood Cancer Journal.
7.
2017
|
|
| 2017
|
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.
Journal of Cancer Survivorship.
11:32-40.
2017
|
|
| 2017
|
Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.
Transfusion.
57:289-295.
2017
|
|
| 2016
|
In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia.
PLoS One.
11.
2016
|
|
| 2016
|
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.
Leukemia.
30:2080-2083.
2016
|
|
| 2016
|
Connect MDS/AML: Design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
BMC Cancer.
16.
2016
|
|
| 2016
|
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Leukemia.
30:1779-1780.
2016
|
|
| 2016
|
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
Leukemia Research.
42:68-74.
2016
|
|
| 2016
|
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: Further results of the E1905 North American Leukemia Intergroup study.
British Journal of Haematology.
172:384-391.
2016
|
|
| 2016
|
Relationship between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVON/SAKK, and MRC/NCRI.
The hematology journal : the official journal of the European Haematology Association / EHA.
101:e284-e286.
2016
|
|
| 2015
|
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: Analysis of 1,892 patients from HOVON/SAKK and SWOG.
The hematology journal : the official journal of the European Haematology Association / EHA.
100:e409-e411.
2015
|
|
| 2015
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study
2015
|
|
| 2015
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clinic Proceedings.
90:996-1000.
2015
|
|
| 2015
|
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - Results of a phase i dose-escalation study.
Clinical Lymphoma, Myeloma and Leukemia.
15:443-449.
2015
|
|
| 2015
|
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study.
British Journal of Haematology.
169:534-543.
2015
|
|
| 2015
|
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Journal of Clinical Oncology.
33:1252-1257.
2015
|
|
| 2015
|
Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.
Current Opinion in Hematology.
22:108-115.
2015
|
|
| 2015
|
Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy.
Biology of Blood and Marrow Transplantation.
21:559-564.
2015
|
|
| 2015
|
Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission.
American Journal of Hematology.
90:242-249.
2015
|
|
| 2015
|
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Leukemia Research.
39:183-191.
2015
|
|
| 2015
|
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Blood.
125:1367-1376.
2015
|
|
| 2015
|
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA.
100:331-335.
2015
|
|
| 2014
|
A multicenter phase l/ll study of obatoclax mesylate administered as a 3- Or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
PLoS One.
9.
2014
|
|
| 2014
|
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
British Journal of Haematology.
167:62-68.
2014
|
|
| 2014
|
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905.
Journal of Clinical Oncology.
32:1242-1248.
2014
|
|
| 2014
|
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Leukemia Research.
38:329-333.
2014
|
|
| 2014
|
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson.
Leukemia.
28:289-292.
2014
|
|
| 2014
|
Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A university of chicago phase 2 consortium trial.
Clinical Cancer Research.
20:490-498.
2014
|
|
| 2014
|
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
British Journal of Haematology.
166:352-359.
2014
|
|
| 2013
|
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Blood.
122:3432-3439.
2013
|
|
| 2013
|
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Investigational New Drugs.
31:1023-1034.
2013
|
|
| 2013
|
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Blood.
121:4854-4860.
2013
|
|
| 2013
|
Expert insights into the contemporary management of older adults with acute myeloid leukemia
2013
|
|
| 2012
|
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia
2012
|
|
| 2012
|
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.
2012
|
|
| 2011
|
Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia.
Blood.
118:5914-5917.
2011
|
|
| 2011
|
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Blood.
118:4258-4264.
2011
|
|
| 2011
|
Improving frontline treatment for chronic myeloid leukemia: Emerging evidence for use of nilotinib and dasatinib.
Clinical advances in hematology & oncology : H&O.
9:734-745.
2011
|
|
| 2011
|
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
Clinical Cancer Research.
17:2679-2692.
2011
|
|
| 2011
|
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood.
117:3294-3301.
2011
|
|
| 2011
|
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Cancer.
117:1253-1261.
2011
|
|
| 2011
|
Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer.
Expert Opinion on Therapeutic Targets.
15:253-264.
2011
|
|
| 2010
|
Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.
Blood.
116:4958-4967.
2010
|
|
| 2010
|
Has there been progress in the treatment of older patients with acute myeloid leukemia?.
Best Practice and Research: Clinical Haematology.
23:495-501.
2010
|
|
| 2010
|
NF1 inactivation in adult acute myelogenous leukemia.
Clinical Cancer Research.
16:4135-4147.
2010
|
|
| 2010
|
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Blood.
116:71-80.
2010
|
|
| 2010
|
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Journal of Clinical Oncology.
28:549-555.
2010
|
|
| 2010
|
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
British Journal of Haematology.
148:48-58.
2010
|
|
| 2009
|
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN.
7:984-1023.
2009
|
|
| 2009
|
Myeloid growth factors.
Journal of the National Comprehensive Cancer Network : JNCCN.
7:64-83.
2009
|
|
| 2009
|
NCCN Task Force report: Molecular markers in leukemias and lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN.
7.
2009
|
|
| 2008
|
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.
Blood.
112:1993-2003.
2008
|
|
| 2008
|
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
Cancer Research.
68:1012-1021.
2008
|
|
| 2008
|
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:962-992.
2008
|
|
| 2008
|
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Blood.
111:1584-1593.
2008
|
|
| 2008
|
Myelodysplastic syndromes.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:902-925.
2008
|
|
| 2007
|
In Vitro and In Silico Analysis of Annexin V Binding to Lymphocytes as a Biomarker in Emergency Department Sepsis Studies.
Academic Emergency Medicine.
14:763-771.
2007
|
|
| 2007
|
Institutional experience with voriconazole compared with liposomal amphotericin b as empiric therapy for febrile neutropenia
2007
|
|
| 2007
|
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN.
5:474-496.
2007
|
|
| 2007
|
Myeloid growth factors: Clinical practice guidelines in oncology™.
Journal of the National Comprehensive Cancer Network : JNCCN.
5:188-202.
2007
|
|
| 2007
|
Prognostic factors in elderly patients with AML and the implications for treatment..
Hematology.
420-428.
2007
|
|
| 2006
|
Acute myeloid leukemia: Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
4:16-36.
2006
|
|
| 2006
|
Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
4:58-77.
2006
|
|
| 2005
|
Chronic myelogenous leukemia: Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
3:732-755.
2005
|
|
| 2004
|
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia..
Current hematology reports.
3:47-53.
2004
|
|
| 2003
|
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.
Journal of Clinical Oncology.
21:3512-3519.
2003
|
|
| 2003
|
Recent progress in the treatment of myelodysplastic syndrome in adult patients.
Current Opinion in Oncology.
15:1-9.
2003
|
|
| 2002
|
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Leukemia.
16:1627-1636.
2002
|
|
| 2000
|
NCCN Practice Guidelines for Acute Myelogenous Leukemia..
Oncology (Williston Park, N.Y.).
14:53-61.
2000
|
|
| 2000
|
NCCN Practice Guidelines for Chronic Myelogenous Leukemia..
Oncology (Williston Park, N.Y.).
14:229-240.
2000
|
|
| 2000
|
Reversible pulmonary hypertension in POEMS syndrome - Another etiology of triggered pulmonary vasculopathy?.
Canadian Journal of Cardiology.
16:1007-1012.
2000
|
|
| 1988
|
Cytoskeletal actin gene families of Xenopus borealis and Xenopus laevis.
Journal of Molecular Evolution.
27:17-28.
1988
|
|
| 1988
|
Modulation of microfilament protein composition by transfected cytoskeletal actin genes.
Molecular and Cellular Biology.
8:1790-1794.
1988
|
|
| 1988
|
Nucleotide sequence and expression of the human skeletal α-actin gene: Evolution of functional regulatory domains.
Genomics.
3:323-336.
1988
|
|
| 1988
|
Structure, chromosome location, and expression of the human γ-actin gene: Differential evolution, location, and expression of the cytoskeletal β- and γ-actin genes.
Molecular and Cellular Biology.
8:1775-1789.
1988
|
|
| 1986
|
Nucleotide sequence of the human γ cytoskeletal actin mRNA: Anomalous evolution of vertebrate non-muscle actin genes.
Nucleic Acids Research.
14:5275-5294.
1986
|
|
| 1981
|
Histone genes are located at the sphere loci of newt lampbrush chromosomes
1981
|
|
| 1981
|
Characterization of a cloned histone gene cluster of the newt notophthalmus viridescens.
Nucleic Acids Research.
9:2281-2295.
1981
|
|
| 1981
|
Histone gene clusters of the newt notophthalmus are separated by long tracts of satellite DNA.
Cell.
24:639-647.
1981
|
|
| 1980
|
Satellite DNA is transcribed on lampbrush chromosomes [24].
Nature.
283:686-688.
1980
|
|
| 1980
|
Cytological evidence of transcription of highly repeated DNA sequences during the lampbrush stage in Triturus cristatus carnifex
1980
|
|
